Shots:

• Samsung Biologics entered into a manufacturing collaboration with AstraZeneca for ~$380M for the production of drug substances and drug products. Samsung Biologics manufactures AstraZeneca’s AZD7442 & is expected the production of cancer immunotherapy in 2022
• The recent expansion is based on May 2021 agreement, followed by the Sept 2020 agreement. Additionally, AZD7442 received a EUA from the US FDA for COVID-19 prevention and is also authorized for use in Italy, France, and Bahrain
• AZD7442 has the potential to complement national vaccination programs by providing additional protection who are at increased risk of an inadequate response to a COVID-19 vaccine

Ref: Samsung Biologics | Image: AstraZeneca